Alzheimer's Association to CMS: Ditch Restraints on Amyloid Drugs

With novel drug lecanemab on the horizon, the Alzheimer Association is asking the CMS to reverse its policy and provide full and unrestricted coverage to FDA-approved anti-amyloid agents.

Related Keywords

Robert Egge ,Joanne Pike ,Centers For Medicare Medicaid Services ,Alzheimer Association ,National Coverage Determinations ,Drug Administration ,Medicaid Services ,Chiquita Brooks Lasure ,Medscape Medical ,New England Journal ,Alzheimers Disease ,Lzheimer Disease ,Medicare ,Dementia ,Medicaid ,Noncommunicable Diseases ,Non Communicable Diseases ,Cd ,Wasting ,